PMID- 37443200
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20231124
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Jul 13
TI  - Salivary ultrasonography and histopathologic evaluation of secondary Sjogren's 
      syndrome in rheumatoid arthritis patients.
PG  - 11339
LID - 10.1038/s41598-023-38469-z [doi]
LID - 11339
AB  - Novel modalities, such as salivary ultrasonography (SGUS) and shear wave 
      elastography (SWE), have previously been introduced to evaluate Sjogren's 
      syndrome (SS). However, in secondary SS (sSS), the diagnostic performance of SGUS 
      and its relationship with clinicopathological characteristics have not yet been 
      clearly defined. In this study, we aimed to investigate sSS in RA patients using 
      SGUS and SWE and sought to determine its pathological correlations. Thirty-one RA 
      patients who presented with sicca symptoms were included to be evaluated on SS, 
      and were compared with 18 primary SS (pSS) patients. All subjects were assessed 
      through SGUS, SWE, and conventional diagnostic approaches for SS, including minor 
      salivary gland biopsy (MSGB). In SGUS evaluation, two separate scoring systems, 
      suggested by Hocevar and OMERACT, were used. Among 31 RA patients with sicca 
      symptoms, 19 (61.2%) were diagnosed as sSS. Similar to pSS, SGUS showed good 
      diagnostic performance (sensitivity 68.4% and 78.9%, and specificity 91.7% and 
      75.0% for Hocever and OMERACT, respectively) in differentiating sSS from RA 
      patients with simple sicca symptoms. The sSS and pSS patients exhibited 
      significantly higher lymphoid infiltration areas in MSGB than RA patients without 
      SS. Focus score and lymphoid infiltration areas correlated well with sonographic 
      severity. Severity of fibrosis in MSGB showed better positive correlation with 
      SWE than with SGUS. Similar to pSS, SGUS shows good diagnostic performance for 
      sSS in RA patients. SWE reflects histopathologic chronicity of MSGB well in both 
      pSS and sSS.
CI  - (c) 2023. The Author(s).
FAU - Park, Youngjae
AU  - Park Y
AD  - Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Oh, Minae
AU  - Oh M
AD  - Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Lee, Youn Soo
AU  - Lee YS
AD  - Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea. lys9908@catholic.ac.kr.
FAU - Kim, Wan-Uk
AU  - Kim WU
AD  - Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 
      wan725@catholic.ac.kr.
AD  - Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic 
      University of Korea, Seoul, Korea. wan725@catholic.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230713
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 89022-11-7 (2'-carbomethoxyphenyl 4-guanidinobenzoate)
SB  - IM
MH  - Humans
MH  - *Sjogren's Syndrome/pathology
MH  - Salivary Glands/diagnostic imaging/pathology
MH  - Ultrasonography
MH  - Salivary Glands, Minor/pathology
PMC - PMC10344871
COIS- The authors declare no competing interests.
EDAT- 2023/07/14 13:06
MHDA- 2023/07/17 06:42
PMCR- 2023/07/13
CRDT- 2023/07/13 23:50
PHST- 2023/02/28 00:00 [received]
PHST- 2023/07/08 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/07/14 13:06 [pubmed]
PHST- 2023/07/13 23:50 [entrez]
PHST- 2023/07/13 00:00 [pmc-release]
AID - 10.1038/s41598-023-38469-z [pii]
AID - 38469 [pii]
AID - 10.1038/s41598-023-38469-z [doi]
PST - epublish
SO  - Sci Rep. 2023 Jul 13;13(1):11339. doi: 10.1038/s41598-023-38469-z.